Study registration: *
Publication Skowronski D, Clin Infect Dis, 2021
Dates: 2020-12-31 to 2021-05-01
Funding: No specific funding (No external funding was provided for this work.)
Conflict of interest: Yes (D. M. S. is Principal or co-Investigator on grants from the Michael Smith Foundation for Health Research, the Public Health Agency of Canada, and the Canadian Institutes of Health Research paid to her institution and unrelated to the current work. M. K. received grants/contracts paid to his institution from Roche, Hologic, and Siemens, unrelated to this work. M. S. has been an investigator on projects, unrelated to the current work, funded by GlaxoSmithKline, Merck, Pfizer, Sanofi- Pasteur, Seqirus, Symvivo (Investigator on grant for COVID-19 vaccine trial), and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.)
Description of participants: Elderly aged 70 and older in communities in British Colombia, Canada
Follow-up duration (months): 4.00
|Variant description :
Variant name: Gamma|
Evidence: Direct evidence (effectiveness determined by sequencing cases)
In addition to the published report, the supplementary material were used in data extraction and risk of bias assessment.
Concerns regarding uncontrolled confounding and bias in selection of participants into the study.